Document is current
Any future updates will be listed below
-
Authors
Liu, Baoer
Korkmaz, Brice
Kraft, Patricia
Mayer, Tobias
Sayour, Alex A.
Grundl, Marc A.
Domain, Roxane
Karck, Matthias
Szabó, Gábor
Korkmaz-Icöz, Sevil https://orcid.org/0000-0003-3613-5807
-
Funding
Funding for this research was provided by:
Ministere de l’Enseignement Superieur et de la Recherche
Region Centre Val de Loire
Universitätsklinikum Heidelberg
- License Information
-
More Information
Article History
Received: 23 May 2023
Accepted: 25 October 2023
First Online: 9 November 2023
Declarations
:
: The approval was obtained by the Ethical Committee of the Regional Council of Karlsruhe, Germany for Animal Experimentation (G257/20).
: Dr. M. A. Grundl is employed by Boehringer Ingelheim Pharma GmbH & Co KG, Biberach a.d. Riss, Germany. Dr B. Korkmaz has been paid for the time spent as a committee member for advisory boards (Brensocatib Advisory Board (BRAB) INSMED, USA), other forms of consulting (Boehringer Ingelheim (Germany), Neuprozyme Therapeutics Aps (Denmark), Santhera Pharmaceuticals (Switzerland), Chiesi (Italy), Gerson Lehrman Group (GLG) (USA), symposium organisation (INSMED) and travel support, lectures or presentations, outside the submitted work. Other authors declare no competing financial interests.
